Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal conjugate vaccine GSK134612 · 1 trial · 1 indication
Vaccine response was defined as: For initially seronegative subjects (pre-vaccination rSBA titer below 1:8), antibody titer greater than or equal to (≥) 1:32 at post-vaccination; for initially seropositive subjects, antibody titer at post-vaccination ≥ 4 fold the pre-vaccination antibody titer.
| Arm | Type | Description |
|---|---|---|
| Menitorix Group | EXPERIMENTAL | Subjects who were primed with Menitorix™ (Hib-MenC-TT) + Priorix™ (MMR) vaccines in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1). The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm. |
| Meningitec + Hiberix Group | EXPERIMENTAL | Subjects who were primed with Meningitec™ (MCC) + Hiberix™ (Hib) + Priorix™ (MMR) vaccine in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1). The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm. |
| Name | Type | Description |
|---|---|---|
| Meningococcal conjugate vaccine GSK134612 | BIOLOGICAL | Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm |
Inclusion Criteria: * Subjects' parent(s)/Legally Acceptable Representative(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol. * A male or female between, and including, 84 and 95 months of age at the time of the booster vaccination. * Written in...
Meningococcal conjugate vaccine GSK134612 is used for meningococcal infections, a type of bacterial infection that can cause meningitis and sepsis. It is being developed by GSK plc as a vaccine to help prevent these serious infections.
GSK plc, traded on the stock exchange under the ticker GSK, is developing Meningococcal conjugate vaccine GSK134612. The company is conducting clinical trials to evaluate the vaccine's safety and effectiveness in preventing meningococcal infections.
Meningococcal conjugate vaccine GSK134612 is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and efficacy.
Meningococcal conjugate vaccine GSK134612 has one completed Phase 3 clinical trial, identified as NCT01777308. This trial studied the vaccine's immunogenicity, reactogenicity, and safety when administered six years after a primary MenC vaccination in healthy subjects who were 12-18 months old at the time of primary vaccination.
Yes, Meningococcal conjugate vaccine GSK134612 is also known as MenACWY-TT. The clinical trial NCT01777308 refers to it as GSK Biologicals' MenACWY-TT vaccine, indicating that GSK134612 and MenACWY-TT are the same vaccine candidate.